Phio Pharmaceuticals (PHIO)
(Delayed Data from NSDQ)
$5.05 USD
-0.80 (-13.60%)
Updated Jul 12, 2024 03:57 PM ET
After-Market: $5.09 +0.04 (0.79%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PHIO 5.05 -0.80(-13.60%)
Will PHIO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PHIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHIO
PHIO Jumps 91% on Encouraging Preclinical Cancer Drug Data
PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up
PHIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Phio Pharmaceuticals Corp. (PHIO) Reports Q3 Loss, Lags Revenue Estimates
What Makes Phio Pharmaceuticals Corp. (PHIO) a New Buy Stock
PTC Therapeutics (PTCT) Halts Huntington's Disease Study in US
Other News for PHIO
Phio Pharmaceuticals Shareholders Approve Key Proposals
Phio Pharmaceuticals And 2 Other Stocks Under $2 Insiders Are Buying
Sypris Solutions And 3 Other Stocks Under $2 Insiders Are Buying
Phio Pharmaceuticals files for $100M mixed shelf
Phio Pharmaceuticals files $100M mixed securities shelf